Saxagliptin is an anti-diabetic drug that is taken orally. It is majorly used for type 2 diabetes. The drug is commercially available under the trade name Onglyza.
Access Full Report Summary: https://www.alliedmarketresearch.com/saxagliptin-market
The global saxagliptin market is driven by factors such as increasing incidence of diabetes, growing risk factors such as changing lifestyle, reduced physical exercise that lead to diabetes, complexities in alternative therapies for diabetes, and high obesity. However, a strict regulatory framework for diabetic drugs and adverse effects of saxagliptin such as upper respiratory tract infection, urinary tract infection, and headache will restrain the market growth. Innovative R&D activities in the field of diabetes therapeutics and growth opportunities in the emerging economies of Asia-Pacific and LAMEA will provide growth opportunities for the market growth.
The report segments the global saxagliptin market based on dosage and region. Based on dosage, it is segmented into 2.5 mg tablets and 5 mg tablets. Geographically, it has been analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Request Free Sample Report: https://www.alliedmarketresearch.com/request-toc-and-sample/4130
Key players that operate in the market include Bristol-Myers Squibb Company and AstraZeneca plc
Purchase and Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/4130